Kidney cancer: Rest ASSUREd, much can be learned from adjuvant studies in renal cancer

Nature Reviews Nephrology 12, 317 (2016). doi:10.1038/nrneph.2016.58 Authors: David D. Chism & W. Kimryn Rathmell The first, highly anticipated randomized trial of adjuvant antiangiogenic therapy in renal cancer was recently reported. Although far from assuring, data from the adjuvant sorafenib or sunitinib for unfavorable renal carcinoma (ASSURE) trial offer a wealth of insights into the disease, treatments, and biological considerations for studies aimed at risk reduction.

http://feeds.nature.com/~r/nrneph/rss/current/~3/lyelVfX-sc4/nrneph.2016.58

Source: Nature Reviews Nephrology - April 24, 2016 Category: Urology & Nephrology Authors: David D. ChismW. Kimryn Rathmell Tags: News and Views Source Type: research